Dr. Zoubeidi's project rated as Top 5 Research Story at PCF Scientific Retreat

Date Posted: 
2018-11-28

Dr. Amina Zoubeidi's project, Reversing Neuroendocrine Prostate Cancer (NEPC), was  rated as one of the Top 5 Research Stories at The 25th Annual Prostate Cancer Foundation Scientific Retreat, held October 26- 28, at the La Costa Resort in Carlsbad, CA.

The Prostate Cancer Foundation's Science Department rated the topics or discoveries discussed during the Scientific Retreat, and described each of the top five on their website. For Dr. Zoubeidi, the description is:
Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal form of prostate cancer that affects ~17% of patients with advanced CRPC. Because this form of prostate cancer is so aggressive, there is an urgent need to develop new and effective treatments for patients with NEPC. PCF-funded researcher Dr. Amina Zoubeidi (Vancouver Prostate Centre) has discovered a “regulator” gene (EZH2) that controls NEPC. When enzalutamide-resistant prostate cancer cells are given EZH2-inhibitors, they revert and become treatable again with enzalutamide. EZH2 inhibitors are now in clinical trials for advanced prostate cancer.

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development